In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vernalis (R&D) Ltd.

http://www.vernalis.com

Latest From Vernalis (R&D) Ltd.

Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy

Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).

M & A Renal

Novartis Aims To Dominate Rare Renal Disorders

Fabhalta and atrasentan are odds-on for approval in C3 glomerulopathy and IgA nephropathy, respectively, but commercial success might be harder to come by.

Clinical Trials Renal

First-To-Market Calliditas Picking Up Speed In IgA Nephropathy

A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.

Sales & Earnings Companies

Regeneron Gene Therapy Reaches New Heights In Restoring Hearing

The US biotech’s DB-OTO has made headlines worldwide after a baby with profound genetic deafness experienced improved hearing to normal levels within 24 weeks after a single intracochlear injection.

Ear Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Cita NeuroPharmaceuticals
    • Vernalis Group plc
UsernamePublicRestriction

Register